SIDT2

Across TCGA pan-cancer cohorts, SIDT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIDT2 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SIDT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIDT2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where SIDT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	21	view →
HNSC	DFS	Median	II,III,IV	0.875	0.711	.005	18	view →
LUAD	OS	Median	II,III,IV	1.000	0.501	.022	12	view →
PDAC	DFS	Quartile	All	0.323	0.539	.006	10	view →
LSCC	DFS	Median	All	0.448	0.873	.016	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIDT2–CCRCC (OS)

Open the CCRCC breakdown →